KYNTRA BIO, INC. Income (Loss) from Continuing Operations, Net of Tax, Including Portion Attributable to Noncontrolling Interest
KYNTRA BIO, INC. (KYNB) reported Income (Loss) from Continuing Operations, Net of Tax, Including Portion Attributable to Noncontrolling Interest of $11.97 million for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-13.
Financial Statements › Expense Statement › Operating Expenses
us-gaap:IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest · last filed 2026-08-13
- KYNTRA BIO, INC. income (loss) from continuing operations, net of tax, including portion attributable to noncontrolling interest for the quarter ending 2026-06-30 was $11.97M.
- KYNTRA BIO, INC. income (loss) from continuing operations, net of tax, including portion attributable to noncontrolling interest for the quarter ending 2026-03-31 was -$15.13M.
- KYNTRA BIO, INC. income (loss) from continuing operations, net of tax, including portion attributable to noncontrolling interest for the quarter ending 2025-12-31 was -$14.61M.
- KYNTRA BIO, INC. income (loss) from continuing operations, net of tax, including portion attributable to noncontrolling interest for the quarter ending 2025-09-30 was -$13.15M.
- KYNTRA BIO, INC. income (loss) from continuing operations, net of tax, including portion attributable to noncontrolling interest for fiscal 2025 was -$58.20M.
- KYNTRA BIO, INC. income (loss) from continuing operations, net of tax, including portion attributable to noncontrolling interest for fiscal 2024 was -$153.10M.
- KYNTRA BIO, INC. income (loss) from continuing operations, net of tax, including portion attributable to noncontrolling interest for fiscal 2023 was -$322.97M.
| Period end | Income (Loss) from Continuing Operations, Net of Tax, Including Portion Attributable to Noncontrolling Interest 3 month | Income (Loss) from Continuing Operations, Net of Tax, Including Portion Attributable to Noncontrolling Interest 6 month | Income (Loss) from Continuing Operations, Net of Tax, Including Portion Attributable to Noncontrolling Interest 9 month | Income (Loss) from Continuing Operations, Net of Tax, Including Portion Attributable to Noncontrolling Interest 12 month |
|---|---|---|---|---|
| 2026-06-30 | $11.97M 10-Q · filed 2026-08-13 | -$3.16M 10-Q · filed 2026-08-13 | -$17.77M derived: sum of 3 quarters · filed 2026-08-13 | -$30.91M derived: sum of 4 quarters · filed 2026-08-13 |
| 2026-03-31 | -$15.13M 10-Q · filed 2026-05-12 | -$29.74M derived: sum of 2 quarters · filed 2026-05-12 | -$42.89M derived: sum of 3 quarters · filed 2026-05-12 | -$56.57M derived: sum of 4 quarters · filed 2026-08-13 |
| 2025-12-31 | -$14.61M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-16 | -$27.76M derived: sum of 2 quarters · filed 2026-03-16 | -$41.44M derived: sum of 3 quarters · filed 2026-08-13 | -$58.20M 10-K · filed 2026-03-16 |
| 2025-09-30 | -$13.15M 10-Q · filed 2025-11-10 | -$26.83M derived: sum of 2 quarters · filed 2026-08-13 | -$43.59M 10-Q · filed 2025-11-10 | -$52.26M derived: sum of 4 quarters · filed 2026-08-13 |
| 2025-06-30 | -$13.68M 10-Q · filed 2026-08-13 | -$30.45M 10-Q · filed 2026-08-13 | -$39.11M derived: sum of 3 quarters · filed 2026-08-13 | -$87.41M derived: sum of 4 quarters · filed 2026-08-13 |
| 2025-03-31 | -$16.77M 10-Q · filed 2026-05-12 | -$25.43M derived: sum of 2 quarters · filed 2026-05-12 | -$73.72M derived: sum of 3 quarters · filed 2026-05-12 | -$120.82M derived: sum of 4 quarters · filed 2026-05-12 |
| 2024-12-31 | -$8.66M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-16 | -$56.96M derived: sum of 2 quarters · filed 2026-03-16 | -$104.05M derived: sum of 3 quarters · filed 2026-03-16 | -$153.10M 10-K · filed 2026-03-16 |
| 2024-09-30 | -$48.29M 10-Q · filed 2025-11-10 | -$95.39M derived: sum of 2 quarters · filed 2025-11-10 | -$144.43M 10-Q · filed 2025-11-10 | |
| 2024-06-30 | -$47.09M 10-Q · filed 2025-08-11 | -$96.14M 10-Q · filed 2025-08-11 | ||
| 2024-03-31 | -$49.05M 10-Q · filed 2025-05-12 | |||
| 2023-12-31 | -$322.97M 10-K · filed 2025-03-17 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Transcode Therapeutics, Inc. (RNAZ) | United States | $0.029B | -0.12 |
| Hepion Pharmaceuticals, Inc. (HEPA) | United States | $0.029B | -0.62 |
| IGC Pharma, Inc. (IGC) | United States | $0.029B | -5.98 |
| BeyondSpring Inc. (BYSI) | United States | $0.031B | -10.95 |
| AYTU BIOPHARMA, INC (AYTU) | United States | $0.025B | -1.62 |
| NANOVIRICIDES, INC. (NNVC) | United States | $0.031B | |
| CHINA PHARMA HOLDINGS, INC. (CPHI) | $0.032B | ||
| NextCure, Inc. (NXTC) | United States | $0.024B | -0.15 |
| TherapeuticsMD, Inc. (TXMD) | United States | $0.024B | -117.87 |
| Propanc Biopharma, Inc. (PPCB) | $0.032B | -0.13 |